Hemodialysis initiation for a case of end-stage renal disease with hemorrhagic-acquired F13 deficiency-Reference-Cited by-同舟云学术

Hemodialysis initiation for a case of end-stage renal disease with hemorrhagic-acquired F13 deficiency

Published:2015 Issue:1 Volume:48 Page:57-60
ISSN:1340-3451
Container-title:Nihon Toseki Igakkai Zasshi
language:en
Short-container-title:Nihon Toseki Igakkai Zasshi

Author:

Kanda Sohei¹,Saito Mitsuru¹,Fukuda Hisami²,Yamamoto Ryohei¹,Koizumi Atsushi¹,Igarashi Ryoma¹,Chiba Shuji¹,Numakura Kazuyuki¹,Akihama Susumu¹,Inoue Takamitsu¹,Narita Shintaro¹,Tsuchiya Norihiko¹,Satoh Shigeru³,Habuchi Tomonori¹

Affiliation:

1. Department of Urology, Akita University Graduate School of Medicine

2. Fujiwara Memorial Hospital

3. Center for Kidney Disease and Transplantation, Akita University Hospital

Publisher

Japanese Society for Dialysis Therapy

Subject

Organic Chemistry,Biochemistry

Reference6 articles.

1. 1) Hiwatashi A, Usui J, Sato C, Hasegawa Y, Yamagata K. Induction of hemodialysis therapy in a case with factor XIII deficiency. Clin Exp Nephrol 2011; 15: 791-2.

2. 3) Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 5: 245-90.

3. 4) Ichinose A. Pathophysiology of transglutaminase including Factor XIII. In: Tanaka K, Davie EW, eds. Recent Advances in Thrombosis and Hematostasis 2008. Springer, 2008; 348-60.

4. 5) Ichinose A. Extracellular transglutaminase: factor XIII. Prog Exp Tumor Res 2005; 38: 192-208.

5. 11) Bajo MA, del Peso G, Jimenez V, et al. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders. Adv Perit Dial 2000; 16: 170-3.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring Factor XIII Inhibitors in Patients with Factor XIII Deficiency: A Case Report and Systematic Review of Current Practices in Japan;Journal of Clinical Medicine;2022-03-18